A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children ’s Oncology Group Phase 1 and Pilot Consortium Trial (ADVL1315)

ConclusionsIn children with refractory solid tumors, the maximum tolerated and recommended dose of axitinib appears to be 2.4 mg/m2/dose, which provides PK exposures similar to those of adults.

Source: Cancer - November 5, 2018 Category: Cancer & Oncology Authors: James I. Geller, Elizabeth Fox, Brian K. Turpin, Stuart L. Goldstein, Xiaowei Liu, Charles G. Minard, Rachel A. Kudgus, Joel M. Reid, Stacey L. Berg, Brenda J. Weigel Tags: Original Article Source Type: research